Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

D. Thaci, S. Piaserico, R. B. Warren, A. K. Gupta, W. Cantrell, Z. Draelos, P. Foley, A. Igarashi, R. G. Langley, A. Asahina, M. Young, M. Falqués, I. Pau-Charles, A. M. Mendelsohn, S. J. Rozzo, K. Reich

Research output: Contribution to journal › Article › peer-review

64 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology